Freedom of Information Request: 0337 2019/20
- Please complete the number of patients treated with Synagis (palivizumab) in the grid below. Please note that the total number of patients (A to E) in each column must add to total patients in the last row in the corresponding column.
| Patients / babies treated with Synagis in the last three years | Total number patients treated with Synagis (Palivizumab)
April 2018 to March 2019 |
Total number patients treated with Synagis (Palivizumab)
April 2017 to March 2018 |
Total number patients treated with Synagis (Palivizumab)
April 2016 to March 2017 |
| A. Total number of patients with BPD / CLD diagnosis | |||
| B. Total number of patients with CHD diagnosis | |||
| C. Total number of <29wga (without BPD/CHD diagnosis) | |||
| D. Total number of multiple births immunised (without BPD/CHD diagnosis) | |||
| E. Other patients (please specify:
_____________________________________) |
|||
| Total number of patients[1] | 42 | 43 | 42 |
[1] Total patients treated with Synagis in each of the last 3 years
BPD: bronchopulmonary dysplasia; CLD: Chronic Lung Disease; CHD: congenital heart disease
2. Please advise which OPCS codes are used within your Trust to code respiratory syncytial virus (RSV) prophylaxis treatment.
| Code Description | Used within Trust to indicate patient received RSV prophylaxis treatment? Yes/No |
| X86.5 Respiratory syncytial virus prevention drugs band 1 | Yes |
| X44.2 Intramuscular injection of vaccine | Yes |
| Other (if not listed above, please specify code(s)): We also use the ICD-10 code Z29.2 | |
3. If your Trust does not provide RSV prophylaxis treatment and you refer your patients to another Trust, please state to which Trust(s) patients are referred. Not Applicable
